Acro Biomedical Co., Ltd.

Earnings Score

Market Cap $60.04K
PE -0
Debt $NaN
Cash $2.68K
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$15.15M
EBIT	-$15.14M
ROE	-4K%
ROA	-3K%
Equity	$339.65K
Growth Stability	-769%
PE	-0
PB	0.18
P/S	0.17
Price/Cash	0.04
Gross Margins	18%
Op. Margins	-4K%
Earnings CAGR	-0%
Sales CAGR	-9%
Equity CAGR	22%
Earnings Stability	-0.16
Earnings Growth YoY	-20%
Earnings Growth QoQ	-20%

Sales CAGR 5Y	-33%
Equity CAGR 5Y	-20%
Earnings CAGR 3Y	10%
Sales CAGR 3Y	10%
Equity CAGR 3Y	-20%
Market Cap	$60.04K
Revenue	$360.00K
Assets	$539.15K
Cash	$2.68K
Shares Outstanding	60.04M
Earnings Score	6%
Working Capital	326.67K
Current Ratio	2.64
Shares Growth 3y	12%
Equity Growth QoQ	-17%
Equity Growth YoY	-41%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Acro Biomedical Co Ltd develops and manufactures nutritional products. The company offers cordyceps fungus for medicinal purposes. It also sells cordycepin and cordyceps powder.

SEC Filings

Direct access to Acro Biomedical Co., Ltd. (ACBM) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2023
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2021
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Acro Biomedical Co., Ltd. compare to its competitors?

Not enough data to generate a comparison chart between Acro Biomedical Co., Ltd. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Acro Biomedical Co., Ltd. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%

Stability -16%

loading chart...

Acro Biomedical Co., Ltd. Discounted Cash Flow

Fully customizable DCF calculator online for Acro Biomedical Co., Ltd..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	09/2015	09/2016	09/2017	09/2018	12/2019	12/2020	12/2021	12/2022	TTM
Net Margins	-	-	-0%	5%	-192%	-17%	-643%	-2K%	-
ROA	-	-	-0%	35%	-45%	-13%	-1K%	-2K%	-3K%
ROE	-	294%	-0%	34%	-47%	-17%	-1K%	-3K%	-4K%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	09/2015	09/2016	09/2017	09/2018	12/2019	12/2020	12/2021	12/2022	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-298%	-769%	-	-	-769%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-769%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	09/2015	09/2016	09/2017	09/2018	12/2019	12/2020	12/2021	12/2022	CAGR 5Y
Revenue YoY growth	-	-	-	1K%	-98%	255%	74%	-45%	-33%
Earnings YoY growth	-	-9%	-95%	-19K%	-189%	-68%	6K%	106%	-
Equity YoY growth	-	-152%	-4K%	143%	-36%	-14%	-6%	-24%	-20%
FCF YoY growth	-	-	-	-	-	-	-	-	-